Eli Lilly to preserve limited patient access to cancer drug Lartruvo after withdrawing it
The planned withdrawal follows the January failure of a Phase III trial to back up the study used for Lartruvo's accelerated approval. Following the announcement, the FDA and EMA recommended no new patients receive the drug.